Molecular mechanism linking a novel PCSK9 copy number variant to severe hypercholesterolemia.
Atherosclerosis
; 304: 39-43, 2020 07.
Article
em En
| MEDLINE
| ID: mdl-32585424
ABSTRACT
BACKGROUND AND AIMS:
A 42 year-old male with premature atherosclerosis, severe dyslipidemia and resistance to treatment with high dose statin and a recommended dose of a PCSK9 inhibitor, was found to have a duplication of the PCSK9 gene. However, the clinical phenotype, which included a more than 15-fold elevation in circulating PCSK9, was unexpected given that he had one additional gene copy.METHODS:
Here we have carried out whole genome sequencing and transcriptional reporter assays to investigate the molecular mechanism leading to this unusual FH phenotype.RESULTS:
The PCSK9 duplication was found to contain the full coding sequence but with an 829 bp shorter 3'-untranslated region (UTR) sequence. All possible rearrangements include a head-to-head fusion between a completely duplicated PCSK9 and a chromosomal region, normally situated ~80 kb away, that includes HNF4 and USF1 binding sites that could promote transcription of the PCSK9 gene. Transcriptional reporter assays demonstrated that a construct harboring the HNF4 binding site significantly increased the promoter activity by 2.5-fold with a smaller effect noted for a USF1 construct.CONCLUSIONS:
Here we describe, in a patient with resistant hypercholesterolemia, a novel PCSK9 gene rearrangement that enables upregulation of PCSK9 expression by allowing proximity to an active enhancer binding to HNF4A.Palavras-chave
Texto completo:
1
Base de dados:
MEDLINE
Assunto principal:
Variações do Número de Cópias de DNA
/
Pró-Proteína Convertase 9
/
Hipercolesterolemia
Idioma:
En
Ano de publicação:
2020
Tipo de documento:
Article